Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any duration), or HIV-1 treatment (\< 10 days therapy total) \> 1 month prior to screening is permitted
HIV-1 ribonucleic acid (RNA) ≥ 200 copies/mL at screening
Current Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection
Clareo Health | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
